Gaston K Rivera

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Transfer of complex frontline anticancer therapy to a developing country: the St. Jude osteosarcoma experience in Chile
    Gaston K Rivera
    International Outreach Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:1143-6. 2008
  2. ncbi request reprint Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia
    Gaston K Rivera
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 103:368-76. 2005
  3. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 104:2690-6. 2004
  4. ncbi request reprint Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Departments of Hematology Oncology, Biostatistics, and Pathology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis TN 38105 2794, USA
    Blood 100:2399-402. 2002
  5. ncbi request reprint Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 349:640-9. 2003
  6. doi request reprint Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Cancer 112:1983-91. 2008
  7. ncbi request reprint Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia
    Thierry Dervieux
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Pharmacol Ther 73:506-16. 2003
  8. pmc A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
    Elaine Coustan-Smith
    Department of Hematology Oncology, and International Outreach Progrm, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 108:97-102. 2006
  9. ncbi request reprint Results of therapy for acute lymphoblastic leukemia in black and white children
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 290:2001-7. 2003
  10. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Transfer of complex frontline anticancer therapy to a developing country: the St. Jude osteosarcoma experience in Chile
    Gaston K Rivera
    International Outreach Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:1143-6. 2008
    ..Jude Children's Research Hospital (sponsor) and Calvo Mackenna Hospital (CMH, partner), a public pediatric hospital and national center for the treatment of bone tumors in Santiago, Chile...
  2. ncbi request reprint Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia
    Gaston K Rivera
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 103:368-76. 2005
    ..The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy...
  3. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 104:2690-6. 2004
    ..01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether...
  4. ncbi request reprint Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Departments of Hematology Oncology, Biostatistics, and Pathology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis TN 38105 2794, USA
    Blood 100:2399-402. 2002
    ..007). These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL...
  5. ncbi request reprint Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 349:640-9. 2003
    ..We determined the long-term survival and the rates of health insurance coverage, marriage, and employment among patients who had attained at least 10 years of event-free survival...
  6. doi request reprint Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Cancer 112:1983-91. 2008
    ..The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse...
  7. ncbi request reprint Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia
    Thierry Dervieux
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Pharmacol Ther 73:506-16. 2003
    ..Methotrexate is postulated to enhance mercaptopurine activation to thioguanine (INN, tioguanine) nucleotides, but the interaction has never been studied in vivo in cancer cells...
  8. pmc A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
    Elaine Coustan-Smith
    Department of Hematology Oncology, and International Outreach Progrm, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 108:97-102. 2006
    ..Thus, this new assay would enable most treatment centers to identify a high proportion of children with ALL who have an excellent early treatment response and a high likelihood of cure...
  9. ncbi request reprint Results of therapy for acute lymphoblastic leukemia in black and white children
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 290:2001-7. 2003
    ..Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials...
  10. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007
    ..Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia...
  11. ncbi request reprint Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia
    Mathew J Edick
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, and College of Pharmacy, The University of Tennessee, Memphis 38105, USA
    J Clin Oncol 21:1340-6. 2003
    ..To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL)...
  12. ncbi request reprint Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
    Mary V Relling
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 101:3862-7. 2003
    ..Even when children receiving irradiation were excluded, the incidence was still higher in those receiving G-CSF (P =.019). In the setting of intensive antileukemic therapy, short-term use of G-CSF may increase the risk of t-ML...
  13. ncbi request reprint A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia
    John Carl Panetta
    St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Cancer Chemother Pharmacol 50:419-28. 2002
    ..These differences provide mechanistic and treatment insights for lineage and ploidy differences in MTXPG accumulation in human leukemia cells in vivo...
  14. ncbi request reprint De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo
    Thierry Dervieux
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital and University of Tennessee, Memphis, 38105, USA
    Blood 100:1240-7. 2002
    ....
  15. ncbi request reprint Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia
    Susana C Raimondi
    Department of Pathology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 98:2715-22. 2003
    ..In addition, the authors determined whether subdivision of the hypodiploid category served a prognostic purpose for these patients...
  16. ncbi request reprint Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Blood Cancer 44:138-41. 2005
    ..We therefore sought to determine if detection of relapse by blood counts before the onset of symptoms provided any clinical benefit...
  17. ncbi request reprint Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital and the University of Tennessee, Memphis, TN 38105, USA
    Blood 100:52-8. 2002
    ..Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome...
  18. ncbi request reprint Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia
    Scott C Howard
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    JAMA 288:2001-7. 2002
    ..Traumatic or bloody lumbar puncture (LP) reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic leukemia (ALL). Little is known about the risk factors for traumatic and bloody LP...
  19. ncbi request reprint Establishment of a pediatric HSCT program in a public hospital in Chile
    Julia Palma
    Bone Marrow Transplant Unit, Luis Calvo Mackenna Hospital, Santiago, Chile
    Pediatr Blood Cancer 46:803-10. 2006
    ..We reasoned that cure rates could be further improved if transplantation with hematopoietic stem cells were available for patients with chemotherapy-resistant malignancy...